Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...

WASHINGTON (AP) — The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine — the nation's only traditional protein-based option for the coronavirus — is sowing ...

Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...

Ampoules of Novavax's COVID-19 vaccine prepared in Berlin, Germany. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Nuvaxovid becomes the only non-messenger RNA COVID-19 ...

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. • NVAX stock is showing ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. American adults who haven't yet gotten vaccinated against COVID-19 should consider a new option ...

Novavax, Inc. (NASDAQ:NVAX) on Thursday revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate. Leveraging Novavax’s recombinant, protein-based nanoparticle technology and ...

Have you seen ads for the new low-dose COVID vaccine called mNEXSpike and wondered what it's all about? Us too! So we did ...

A recent study has provided the first side-by-side comparison of how three major COVID-19 vaccine types differ in triggering ...